A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer

Circulating tumor cell clusters (CTCcl) have a higher metastatic potential compared to single CTCs and predict long-term outcomes in breast cancer (BC) patients. Because of the rarity of CTCcls, molecular characterization of primary tumors that give rise to CTCcl hold significant promise for better diagnosis and target discovery to combat metastatic BC. In our study, we utilized the reverse-phase protein array (RPPA) and transcriptomic (RNA-Seq) data of 10 triple-negative BC patient-derived xenograft (TNBC PDX) transplantable models with CTCs and evaluated expression of upregulated candidate protein Bcl2 (B-cell lymphoma 2) by immunohistochemistry (IHC). The sample-set consisted of six CTCcl-negative (CTCcl−) and four CTCcl-positive (CTCcl+) models. We analyzed the RPPA and transcriptomic profiles of CTCcl− and CTCcl+ TNBC PDX models. In addition, we derived a CTCcl-specific gene signature for testing if it predicted outcomes using a publicly available dataset from 360 patients with basal-like BC. The RPPA analysis of CTCcl+ vs. CTCcl− TNBC PDX tumors revealed elevated expression of Bcl2 (false discovery rate (FDR) < 0.0001, fold change (FC) = 3.5) and reduced acetyl coenzyme A carboxylase-1 (ACC1) (FDR = 0.0005, FC = 0.3) in CTCcl+ compared to CTCcl− tumors. Genome-wide transcriptomic analysis of CTCcl+ vs. CTCcl− tumors revealed 549 differentially expressed genes associated with the presence of CTCcls. Apoptosis was one of the significantly downregulated pathways (normalized enrichment score (NES) = −1.69; FDR < 0.05) in TNBC PDX tumors associated with CTCcl positivity. Two out of four CTCcl+ TNBC PDX primary tumors had high Bcl2 expression by IHC (H-score > 34); whereas, only one of six CTCcl− TNBC PDX primary tumors met this criterion. Evaluation of epithelial-mesenchymal transition (EMT)-specific signature did not show significant differences between CTCcl+ and CTCcl− tumors. However, a gene signature associated with the presence of CTCcls in TNBC PDX models was associated with worse relapse-free survival in the publicly available dataset from 360 patients with basal-like BC. In summary, we identified the multigene signature of primary PDX tumors associated with the presence of CTCcls. Evaluation of additional TNBC PDX models and patients can further illuminate cellular and molecular pathways facilitating CTCcl formation.

[1]  D. Santini,et al.  A simple immunohistochemical bio-profile incorporating Bcl2 curbs those cases of invasive breast carcinoma for which an Oncotype Dx characterization is needed , 2019, PloS one.

[2]  Chun-chun Xue,et al.  The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis , 2019, Front. Oncol..

[3]  R. Schiff,et al.  Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis , 2019, BMC Cancer.

[4]  Yang Shen,et al.  Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. , 2018, Cancer discovery.

[5]  F. Garcia,et al.  BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score , 2018, BMC Clinical Pathology.

[6]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[7]  Guang-lei Qiao,et al.  Prognostic value of CD44v6 expression in breast cancer: a meta-analysis , 2018, OncoTargets and therapy.

[8]  N. Loman,et al.  Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial , 2018, Breast Cancer Research.

[9]  M. Harada,et al.  Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin , 2018, Oncotarget.

[10]  C. Chen,et al.  The biology and role of CD44 in cancer progression: therapeutic implications , 2018, Journal of Hematology & Oncology.

[11]  K. Hirakawa,et al.  Correction to: Circulating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer , 2017, Biomarker Research.

[12]  R. Schiff,et al.  Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. , 2018, Cancer research.

[13]  Ryan Miller,et al.  WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research , 2017, Nucleic Acids Res..

[14]  Sohee Oh,et al.  BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database , 2017, Cancer research and treatment : official journal of Korean Cancer Association.

[15]  L. D. White,et al.  EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells , 2017, Nature Communications.

[16]  K. Xie,et al.  The Role of CD44 and Cancer Stem Cells. , 2018, Methods in molecular biology.

[17]  Ž. Vujašković,et al.  Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients , 2018, The International journal of biological markers.

[18]  Marilyn M. Li,et al.  Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer , 2018, Breast Cancer Research and Treatment.

[19]  T. Graeber,et al.  Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer , 2018, Annals of Surgical Oncology.

[20]  Mohit Kumar Jolly,et al.  Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric. , 2017, Cancer research.

[21]  Chen Wang,et al.  Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis , 2017, Scientific Reports.

[22]  W. El-Deiry,et al.  Circulating tumor cells: silent predictors of metastasis , 2017, F1000Research.

[23]  Luana Mota Martins,et al.  Bcl-2 antigen expression in luminal A and triple-negative breast cancer , 2017, Medical Oncology.

[24]  S. Tomita,et al.  Circulating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer , 2017, Biomarker Research.

[25]  Jing Wang,et al.  WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit , 2017, Nucleic Acids Res..

[26]  D. Ding,et al.  The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis , 2017, Cancer Cell International.

[27]  Yan-ping Wang,et al.  Prognostic Significance of CD24 and CD44 in Breast Cancer: A Meta-Analysis , 2017, The International journal of biological markers.

[28]  François Vaillant,et al.  Patient-derived xenograft (PDX) models in basic and translational breast cancer research , 2016, Cancer and Metastasis Reviews.

[29]  Qi Zhang,et al.  Circulating tumor cell clusters: What we know and what we expect (Review) , 2016, International journal of oncology.

[30]  A. Lánczky,et al.  miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients , 2016, Breast Cancer Research and Treatment.

[31]  Hushan Yang,et al.  Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer , 2016, International journal of molecular sciences.

[32]  J. Hanaoka,et al.  Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors , 2016, ESMO Open.

[33]  P. Bendahl,et al.  Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort , 2016, BMC Cancer.

[34]  Pu Xia,et al.  Prognostic significance of CD44 in human colon cancer and gastric cancer: Evidence from bioinformatic analyses , 2016, Oncotarget.

[35]  Jaime Rodriguez-Canales,et al.  Image Analysis–based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non–small Cell Lung Carcinoma Patients , 2016, Clinical Cancer Research.

[36]  G. Wilson,et al.  The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer , 2016, Stem cells international.

[37]  E. Ben-Jacob,et al.  Stability of the hybrid epithelial/mesenchymal phenotype , 2016, Oncotarget.

[38]  Gen Sheng Wu,et al.  Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis , 2016, OncoTargets and therapy.

[39]  Hushan Yang,et al.  Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer , 2016, Breast Cancer Research and Treatment.

[40]  Hushan Yang,et al.  Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer , 2015, Breast Cancer Research and Treatment.

[41]  F. Akiyama,et al.  Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy , 2015, BMC Cancer.

[42]  M. Daidone,et al.  Did Circulating Tumor Cells Tell us all they Could? The Missed Circulating Tumor Cell Message in Breast Cancer , 2015, The International journal of biological markers.

[43]  Eshel Ben-Jacob,et al.  Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis , 2015, Front. Oncol..

[44]  Y. Miyagi,et al.  Establishment of patient-derived cancer xenografts in immunodeficient NOG mice , 2015, International journal of oncology.

[45]  Sridhar Ramaswamy,et al.  A microfluidic device for label-free, physical capture of circulating tumor cell-clusters , 2015, Nature Methods.

[46]  J. Visvader,et al.  Patient-derived xenograft models of breast cancer and their predictive power , 2015, Breast Cancer Research.

[47]  L. Radová,et al.  BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy , 2015, Tumor Biology.

[48]  C. Shaw,et al.  Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis , 2015, Breast Cancer Research.

[49]  Sridhar Ramaswamy,et al.  Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis , 2014, Cell.

[50]  Prahlad T. Ram,et al.  A pan-cancer proteomic perspective on The Cancer Genome Atlas , 2014, Nature Communications.

[51]  Caroline Dive,et al.  Molecular analysis of circulating tumour cells—biology and biomarkers , 2014, Nature Reviews Clinical Oncology.

[52]  D. Beebe,et al.  Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker. , 2014, Journal of patient-centered research and reviews.

[53]  G. Ball,et al.  Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  Chad A Shaw,et al.  A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. , 2013, Cancer research.

[55]  Matthew E. Ritchie,et al.  Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. , 2013, Cancer cell.

[56]  Klaus Pantel,et al.  Circulating tumor cells: liquid biopsy of cancer. , 2013, Clinical chemistry.

[57]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[58]  F. Hirsch,et al.  Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[59]  Peter Kuhn,et al.  Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors , 2012, Physical biology.

[60]  G. Hortobagyi,et al.  Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer , 2012, International Journal of Clinical Oncology.

[61]  Zoltan Szallasi,et al.  Jetset: selecting the optimal microarray probe set to represent a gene , 2011, BMC Bioinformatics.

[62]  Mark T. W. Ebbert,et al.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.

[63]  O. Sansom,et al.  HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer , 2011, Proceedings of the National Academy of Sciences.

[64]  Matthew E. Ritchie,et al.  Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737 , 2011, Proceedings of the National Academy of Sciences.

[65]  Massimo Cristofanilli,et al.  Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment , 2011, Breast Cancer Research.

[66]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[67]  Caroline Dive,et al.  Circulating tumor cells as a window on metastasis biology in lung cancer. , 2011, The American journal of pathology.

[68]  Shu Ichihara,et al.  Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists , 2011, Modern Pathology.

[69]  M. Tsao,et al.  Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors , 2009, Oncogene.

[70]  Kristine Broglio,et al.  Circulating tumor cells in metastatic breast cancer , 2008, Cancer.

[71]  A. Gennari The Impact of New Chemotherapeutic and Hormone Agents on Survival in a Population-based Cohort of Women with Metastatic Breast Cancer , 2008 .

[72]  K. Gelmon,et al.  The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancer , 2007, Cancer.

[73]  Leon W.M.M. Terstappen,et al.  Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer , 2006, Clinical Cancer Research.

[74]  C. Orlandini,et al.  Survival of metastatic breast carcinoma patients over a 20‐year period , 2005, Cancer.

[75]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[77]  Chan Zeng,et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[79]  M. Ruggiero,et al.  Role of three cancer "master genes" p53, bcl2 and c-myc on the apoptotic process. , 1996, Tumori.

[80]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.